Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Oligoprogressive 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1DEAE-Dextran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligoprogressive × Immune Checkpoint Inhibitors × 30 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡